Maze Therapeutics (MAZE) Competitors $13.35 -0.25 (-1.84%) As of 08/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MAZE vs. CNTA, IBRX, BLTE, ARWR, RXRX, AGIO, OCUL, BHC, DNLI, and TARSShould you be buying Maze Therapeutics stock or one of its competitors? The main competitors of Maze Therapeutics include Centessa Pharmaceuticals (CNTA), ImmunityBio (IBRX), Belite Bio (BLTE), Arrowhead Pharmaceuticals (ARWR), Recursion Pharmaceuticals (RXRX), Agios Pharmaceuticals (AGIO), Ocular Therapeutix (OCUL), Bausch Health Cos (BHC), Denali Therapeutics (DNLI), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry. Maze Therapeutics vs. Its Competitors Centessa Pharmaceuticals ImmunityBio Belite Bio Arrowhead Pharmaceuticals Recursion Pharmaceuticals Agios Pharmaceuticals Ocular Therapeutix Bausch Health Cos Denali Therapeutics Tarsus Pharmaceuticals Maze Therapeutics (NASDAQ:MAZE) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability. Is MAZE or CNTA more profitable? Maze Therapeutics' return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Maze TherapeuticsN/A N/A N/A Centessa Pharmaceuticals N/A -40.39%-29.87% Which has higher valuation and earnings, MAZE or CNTA? Maze Therapeutics has higher revenue and earnings than Centessa Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaze Therapeutics$167.50M3.49$52.23MN/AN/ACentessa Pharmaceuticals$6.85M345.25-$235.76M-$1.79-9.85 Do analysts rate MAZE or CNTA? Maze Therapeutics presently has a consensus price target of $25.60, indicating a potential upside of 91.76%. Centessa Pharmaceuticals has a consensus price target of $28.10, indicating a potential upside of 59.30%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Maze Therapeutics is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of MAZE or CNTA? 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 7.1% of Centessa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer MAZE or CNTA? In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than Maze Therapeutics. MarketBeat recorded 11 mentions for Centessa Pharmaceuticals and 9 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 0.97 beat Centessa Pharmaceuticals' score of 0.30 indicating that Maze Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Centessa Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryMaze Therapeutics beats Centessa Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAZE vs. The Competition Export to ExcelMetricMaze TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$596.37M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E RatioN/A20.4930.2925.74Price / Sales3.49356.37463.41115.83Price / Cash88.8343.0338.2159.48Price / Book2.238.608.826.15Net Income$52.23M-$54.65M$3.25B$265.06M7 Day Performance1.60%5.86%3.70%2.60%1 Month Performance-16.61%8.86%5.84%2.83%1 Year PerformanceN/A13.33%29.92%25.58% Maze Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAZEMaze TherapeuticsN/A$13.35-1.8%$25.60+91.8%N/A$596.37M$167.50M0.00121Earnings ReportGap DownCNTACentessa Pharmaceuticals2.6345 of 5 stars$17.02-0.9%$28.10+65.1%+40.0%$2.30B$6.85M-9.40200Earnings ReportAnalyst ForecastIBRXImmunityBio2.2323 of 5 stars$2.44+1.7%$12.25+402.0%-30.2%$2.27B$14.74M-5.08590News CoverageAnalyst ForecastOptions VolumeGap DownBLTEBelite Bio2.7327 of 5 stars$69.88-0.3%$96.67+38.3%+38.2%$2.23BN/A-51.3810News CoverageEarnings ReportAnalyst RevisionARWRArrowhead Pharmaceuticals4.1504 of 5 stars$16.42+2.2%$43.14+162.7%-17.3%$2.22B$3.55M-12.83400Trending NewsAnalyst RevisionGap DownRXRXRecursion Pharmaceuticals1.4777 of 5 stars$5.36-0.9%$7.00+30.6%-10.2%$2.20B$58.84M-3.01400Gap DownAGIOAgios Pharmaceuticals4.3992 of 5 stars$35.76-3.5%$56.33+57.5%-17.9%$2.15B$36.50M3.25390Insider TradeOCULOcular Therapeutix4.0884 of 5 stars$12.21-0.7%$17.20+40.9%+58.3%$2.14B$63.72M-9.54230BHCBausch Health Cos4.1629 of 5 stars$5.77+0.2%$9.00+56.0%+35.8%$2.13B$9.63B22.1920,700News CoveragePositive NewsInsider TradeGap UpDNLIDenali Therapeutics4.1798 of 5 stars$13.96-1.9%$33.85+142.5%-35.7%$2.07B$330.53M-5.23430News CoverageEarnings ReportAnalyst RevisionGap DownTARSTarsus Pharmaceuticals1.781 of 5 stars$47.85-0.2%$66.67+39.3%+103.1%$2.01B$182.95M-20.5450Insider Trade Related Companies and Tools Related Companies Centessa Pharmaceuticals Competitors ImmunityBio Competitors Belite Bio Competitors Arrowhead Pharmaceuticals Competitors Recursion Pharmaceuticals Competitors Agios Pharmaceuticals Competitors Ocular Therapeutix Competitors Bausch Health Cos Competitors Denali Therapeutics Competitors Tarsus Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAZE) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access